Naval G. Daver, MD – Azacitidine, Venetoclax, and Trametinib

Naval G. Daver, MD is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. 

Naval G. Daver, MD, a faculty member at MD Anderson Cancer Center, co-chaired a successful symposium in Houston, Texas, featuring engaging presentations and active participation from junior faculty. Naval’s presentation focused on groundbreaking triplet therapies for acute myeloid leukemia patients unable to undergo intensive chemotherapy.

Register – AML-ALL US Focus Meeting 2023

aml-allus2023.md-education.com

Naval G. Daver, MD showcased the groundbreaking Azacitidine, Venetoclax, and Trametinib triplet therapy for acute myeloid leukemia, underscoring the potential for improved patient outcomes and higher cure rates. The meeting’s success and potential for growth emphasize its role in fostering interactions, learning, and advancements in leukemia treatment.